JLC acquires BINEX

Published: 2008-01-29 06:59:00

Updated: 2008-01-29 06:59:00

JLC, a local investment company, said January 21 it has signed a take-over contract with BINEX, a biopharmaceutical firm, to set foot in the domestic pharmaceutical sector.

We strongly believe that the takeover will add growth momentum to BINEX's research capability. We will transform BINEX in...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK